title: Role of P2X7 receptors in the development of diabetic retinopathy.
abstract: The P2X7 receptor is one of the members of the family of purinoceptors which are ligand-gated membrane ion channels activated by extracellular adenosine 5'-triphosphate. A unique feature of the P2X7 receptor is that its activation can result in the formation of large plasma membrane pores that allow not only the flux of ions but also of hydrophilic molecules of up to 900 Da. Recent studies indicate that P2X7-mediated signaling can trigger apoptotic cell death after ischemia and during the course of certain neurodegenerative disorders. Expression of the P2X7 receptor has been demonstrated in most types of cells in the retina. This purinoceptor mediates the contraction of pericytes and regulates the spatial and temporal dynamics of the vasomotor response through cell-to-cell electrotonic transmission within the microvascular networks. Of potential clinical significance, investigators have found that diabetes markedly boosts the vulnerability of retinal microvessels to the lethal effect of P2X7 receptor activation. This purinergic vasotoxicity may result in reduced retinal blood flow and disrupted vascular function in the diabetic retina. With recent reports indicating an association between P2X7 receptor activation and inflammatory cytokine expression in the retina, this receptor may also exacerbate the development of diabetic retinopathy by a mechanism involving inflammation.
authors.affiliation: Tetsuya Sugiyama, Nakano Eye Clinic of Kyoto Medical Co-operative, Kyoto 604-8404, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Sugiyama
keywords: Diabetic retinopathy; Interleukin-1β; P2X7 receptor; Retinal microvessels; Tumor necrosis factor-α; Vasotoxicity
references.citation: Purinergic Signal. 2012 Sep;8(3):375-417
references.pmid: 22547202
references.citation: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3236-43
references.pmid: 20071682
references.citation: Nature. 2001 Dec 13;414(6865):813-20
references.pmid: 11742414
references.citation: Physiol Rev. 2002 Oct;82(4):1013-67
references.pmid: 12270951
references.citation: Brain Res Mol Brain Res. 1998 Nov 12;62(1):106-9
references.pmid: 9795168
references.citation: Arch Ophthalmol. 2006 Aug;124(8):1143-9
references.pmid: 16908817
references.citation: Can J Ophthalmol. 2002 Jun;37(4):221-7
references.pmid: 12095095
references.citation: Am J Physiol Cell Physiol. 2005 Mar;288(3):C568-76
references.pmid: 15496477
references.citation: J Comp Neurol. 2004 Apr 19;472(1):13-23
references.pmid: 15024749
references.citation: J Physiol. 2012 May 15;590(10):2285-304
references.pmid: 22411013
references.citation: Acta Physiol (Oxf). 2010 Jun;199(2):93-147
references.pmid: 20345419
references.citation: Mol Neurobiol. 2012 Aug;46(1):96-113
references.pmid: 22467178
references.citation: Exp Eye Res. 2010 Sep;91(3):425-32
references.pmid: 20599962
references.citation: J Comp Neurol. 2003 May 5;459(3):267-77
references.pmid: 12655509
references.citation: World J Diabetes. 2010 Mar 15;1(1):12-8
references.pmid: 21537423
references.citation: Eye (Lond). 1999 Aug;13 ( Pt 4):497-523
references.pmid: 10692923
references.citation: Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1240-5
references.pmid: 15155383
references.citation: Expert Opin Ther Targets. 2008 May;12(5):647-61
references.pmid: 18410246
references.citation: EMBO J. 2002 Aug 15;21(16):4307-16
references.pmid: 12169633
references.citation: J Neurosci. 2004 Sep 29;24(39):8577-83
references.pmid: 15456831
references.citation: J Clin Invest. 1996 Jun 15;97(12):2883-90
references.pmid: 8675702
references.citation: J Clin Invest. 1995 Mar;95(3):1207-16
references.pmid: 7883969
references.citation: J Physiol. 2003 Sep 15;551(Pt 3):787-99
references.pmid: 12876212
references.citation: J Neurosci. 2000 Aug 15;20(16):5965-72
references.pmid: 10934244
references.citation: Nature. 1994 Oct 6;371(6497):516-9
references.pmid: 7523951
references.citation: Mol Vis. 2013 Sep 28;19:2080-91
references.pmid: 24146541
references.citation: Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5032-8
references.pmid: 17065524
references.citation: Neurosci Lett. 2000 Mar 24;282(3):153-6
references.pmid: 10717414
references.citation: Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2183-91
references.pmid: 15914640
references.citation: Neurochem Int. 2005 Sep;47(4):235-42
references.pmid: 15964665
references.citation: FASEB J. 1993 Aug;7(11):1031-8
references.pmid: 8370472
references.citation: J Neuropathol Exp Neurol. 2004 Jul;63(7):686-99
references.pmid: 15290894
references.citation: Adv Pharmacol. 2011;61:333-72
references.pmid: 21586364
references.citation: Invest Ophthalmol Vis Sci. 2004 Mar;45(3):1026-32
references.pmid: 14985326
references.citation: Br J Pharmacol. 2000 Jul;130(5):963-74
references.pmid: 10882379
references.citation: Diabetologia. 2000 Oct;43(10):1248-56
references.pmid: 11079743